Form 8-K - Current report:
SEC Accession No. 0001213900-25-043699
Filing Date
2025-05-15
Accepted
2025-05-15 08:01:09
Documents
14
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242319-8k_biomxinc.htm   iXBRL 8-K 26305
2 PRESS RELEASE DATED MAY 15, 2025 ea024231901ex99-1_biomxinc.htm EX-99.1 67283
  Complete submission text file 0001213900-25-043699.txt   278486

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phge-20250515.xsd EX-101.SCH 3005
4 XBRL LABEL FILE phge-20250515_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE phge-20250515_pre.xml EX-101.PRE 22352
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0242319-8k_biomxinc_htm.xml XML 3647
Mailing Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003
Business Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003 972 723942377
BiomX Inc. (Filer) CIK: 0001739174 (see all company filings)

EIN.: 823364020 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38762 | Film No.: 25948815
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)